Pipeline

Biothera has a robust pharmaceutical development pipeline based on two active Investigational New Drug (IND) filings with the U.S. Food and Drug Administration.
Phase I Safety Trials
Imprime PGG® has successfully completed three Phase 1 safety studies (single dose, multiple dose, multiple dose combination with an approved drug).
Phase II Clinical Trials
Metastatic Colorectal Cancer (MCRC)
The company has initiated dual-arm clinical trial with MCRC patients to evaluate the safety and efficacy of Imprime PGG in combination with other approved drugs.
- First Arm Therapy: A combination of Imprime PGG, Erbitux® (Cetuximab), a monoclonal antibody from ImClone Systems, and Irinotecan, a chemotherapy drug from Pfizer.
- Second Arm Therapy: A combination of Imprime PGG and Erbitux.
Non Small Cell Lung Cancer (NSCLC)
Biothera expects to launch a dual-arm Phase II clinical trial in NSCLC patients in the third quarter of 2008.
- First Arm Therapy: A combination of Imprime PGG, Avastin® (Bevacizumab), a Genentech monoclonal antibody, and two chemotherapy drugs, Carboplatin and Paclitaxel.
- Second Arm Therapy: A combination of Imprime PGG, Erbitux, Carboplatin and Paclitaxel.
